Literature DB >> 23358539

Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors.

Ignacio Martin-Loeches1, Maria Deja, Despoina Koulenti, George Dimopoulos, Brian Marsh, Antonio Torres, Michael S Niederman, Jordi Rello.   

Abstract

PURPOSE: As per 2005 American Thoracic Society and Infectious Disease Society of America (ATS/IDSA) guidelines for managing hospital-acquired pneumonia, patients with early-onset pneumonia and without risk factors do not need to be treated for potentially resistant microorganisms (PRM).
METHODS: This was a secondary analysis of a prospective, observational, cohort, multicentre study conducted in 27 ICUs from nine European countries.
RESULTS: From a total of 689 patients with nosocomial pneumonia who required mechanical ventilation, 485 patients with confirmed etiology and antibiotic susceptibility were further analysed. Of these patients, 152 (31.3 %) were allocated to group 1 with early-onset pneumonia and no risk factors for PRM acquisition, and 333 (68.7 %) were classified into group 2 with early-onset pneumonia with risk factors for PRM or late-onset pneumonia. Group 2 patients were older and had more chronic renal failure and more severe illness (SAPS II score, 44.6 ± 16.5 vs. 47.4 ± 17.8, p = 0.04) than group 1 patients. Trauma patients were more frequent and surgical patients less frequent in group 1 than in group 2 (p < 0.01). In group 1, 77 patients (50.7 %) had PRM in spite of the absence of classic risk factors recognised by the current guidelines. A logistic regression analysis identified that presence of severe sepsis/septic shock (OR = 3.7, 95 % CI 1.5-8.9) and pneumonia developed in centres with greater than 25 % prevalence of PRM (OR = 11.3, 95 % CI 2.1-59.3) were independently associated with PRM in group 1 patients.
CONCLUSIONS: In patients admitted to ICUs with a prevalence of PRM greater than 25 % or with severe sepsis/septic shock, empiric therapy for group 1 nosocomial pneumonia requiring mechanical ventilation should also include agents likely to be effective for PRM pathogens.

Entities:  

Mesh:

Year:  2013        PMID: 23358539     DOI: 10.1007/s00134-012-2808-5

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  29 in total

1.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

2.  The ventilator-associated pneumonia PIRO score: a tool for predicting ICU mortality and health-care resources use in ventilator-associated pneumonia.

Authors:  Thiago Lisboa; Emili Diaz; Marcio Sa-Borges; Antonia Socias; Jordi Sole-Violan; Alejandro Rodríguez; Jordi Rello
Journal:  Chest       Date:  2008-09-08       Impact factor: 9.410

3.  Impact of clinical severity index, infective pathogens, and initial empiric antibiotic use on hospital mortality in patients with ventilator-associated pneumonia.

Authors:  Chia-Cheng Tseng; Shih-Feng Liu; Chin-Chou Wang; Mei-Lien Tu; Yu-Hsiu Chung; Meng-Chih Lin; Wen-Feng Fang
Journal:  Am J Infect Control       Date:  2012-01-13       Impact factor: 2.918

4.  How many infections are caused by patient-to-patient transmission in intensive care units?

Authors:  Hajo Grundmann; Sina Bärwolff; Adriana Tami; Michael Behnke; Frank Schwab; Christine Geffers; Elke Halle; Ulf B Göbel; Reinhold Schiller; Daniel Jonas; Ingo Klare; Klaus Weist; Wolfgang Witte; Kathrin Beck-Beilecke; Martin Schumacher; Henning Rüden; Petra Gastmeier
Journal:  Crit Care Med       Date:  2005-05       Impact factor: 7.598

Review 5.  Ventilator-associated pneumonia.

Authors:  Jean Chastre; Jean-Yves Fagon
Journal:  Am J Respir Crit Care Med       Date:  2002-04-01       Impact factor: 21.405

6.  Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia.

Authors:  C M Luna; P Vujacich; M S Niederman; C Vay; C Gherardi; J Matera; E C Jolly
Journal:  Chest       Date:  1997-03       Impact factor: 9.410

7.  International study of the prevalence and outcomes of infection in intensive care units.

Authors:  Jean-Louis Vincent; Jordi Rello; John Marshall; Eliezer Silva; Antonio Anzueto; Claude D Martin; Rui Moreno; Jeffrey Lipman; Charles Gomersall; Yasser Sakr; Konrad Reinhart
Journal:  JAMA       Date:  2009-12-02       Impact factor: 56.272

8.  Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia.

Authors:  Daren K Heyland; Peter Dodek; John Muscedere; Andrew Day; Deborah Cook
Journal:  Crit Care Med       Date:  2008-03       Impact factor: 7.598

9.  Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group.

Authors:  F Alvarez-Lerma
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

10.  Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated-pneumonia.

Authors:  Pieter O Depuydt; Dominique M Vandijck; Maarten A Bekaert; Johan M Decruyenaere; Stijn I Blot; Dirk P Vogelaers; Dominique D Benoit
Journal:  Crit Care       Date:  2008-11-17       Impact factor: 9.097

View more
  48 in total

1.  Understanding why resistant bacteria are associated with higher mortality in ICU patients.

Authors:  François Barbier; Thiago Lisboa; Saad Nseir
Journal:  Intensive Care Med       Date:  2015-11-12       Impact factor: 17.440

2.  The road forward in the management of Acinetobacter infections in the ICU.

Authors:  Michael S Niederman; Marin H Kollef
Journal:  Intensive Care Med       Date:  2015-12       Impact factor: 17.440

3.  Risk factors for Pseudomonas aeruginosa pneumonia in the early twenty-first century.

Authors:  Jordi Rello; Bárbara Borgatta; Thiago Lisboa
Journal:  Intensive Care Med       Date:  2013-10-22       Impact factor: 17.440

4.  What's new in ventilator-associated pneumonia?

Authors:  Jordi Rello; Jordi Riera; Ricardo Serrano
Journal:  Intensive Care Med       Date:  2015-06-11       Impact factor: 17.440

5.  A 2015 Update on Ventilator-Associated Pneumonia: New Insights on Its Prevention, Diagnosis, and Treatment.

Authors:  Braden Waters; John Muscedere
Journal:  Curr Infect Dis Rep       Date:  2015-08       Impact factor: 3.725

6.  Multipathogen real-time PCR system adds benefit for my patients: no.

Authors:  Saad Nseir; Pedro Povoa
Journal:  Intensive Care Med       Date:  2015-01-27       Impact factor: 17.440

7.  The research agenda in VAP/HAP: next steps.

Authors:  Michael S Niederman; Ignacio Martin-Loeches; Antoni Torres
Journal:  Intensive Care Med       Date:  2017-02-14       Impact factor: 17.440

8.  Adding risk factors for potentially resistant pathogens, increasing antibiotic pressure and risk creating the "untreatable bacteria": time to change direction.

Authors:  José-Artur Paiva
Journal:  Intensive Care Med       Date:  2013-01-29       Impact factor: 17.440

9.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

10.  De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial.

Authors:  Marc Leone; Carole Bechis; Karine Baumstarck; Jean-Yves Lefrant; Jacques Albanèse; Samir Jaber; Alain Lepape; Jean-Michel Constantin; Laurent Papazian; Nicolas Bruder; Bernard Allaouchiche; Karine Bézulier; François Antonini; Julien Textoris; Claude Martin
Journal:  Intensive Care Med       Date:  2014-08-05       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.